Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2015 2
2016 1
2018 2
2020 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
A highly virulent variant of HIV-1 circulating in the Netherlands.
Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M, Ong SH, Zhao L, Bonsall D, de Cesare M, MacIntyre-Cockett G, Abeler-Dörner L, Albert J, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C; Netherlands ATHENA HIV Observational Cohort†; BEEHIVE Collaboration†. Wymant C, et al. Science. 2022 Feb 4;375(6580):540-545. doi: 10.1126/science.abk1688. Epub 2022 Feb 3. Science. 2022. PMID: 35113714 Free article.
Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial.
Zuily S, Lefèvre B, Sanchez O, Empis de Vendin O, de Ciancio G, Arlet JB, Khider L, Terriat B, Greigert H, Robert CS, Louis G, Trinh-Duc A, Rispal P, Accassat S, Thiery G, Montani D, Azarian R, Meneveau N, Soudet S, Le Mao R, Maurier F, Le Moing V, Quéré I, Yelnik CM, Lefebvre N, Martinot M, Delrue M, Benhamou Y, Parent F, Roy PM, Presles E, Goehringer F, Mismetti P, Bertoletti L, Rossignol P, Couturaud F, Wahl D, Thilly N, Laporte S; COVI-DOSE investigators. Zuily S, et al. EClinicalMedicine. 2023 Jun;60:102031. doi: 10.1016/j.eclinm.2023.102031. Epub 2023 Jun 9. EClinicalMedicine. 2023. PMID: 37350990 Free PMC article.
Utility of hyposmia and hypogeusia for the diagnosis of COVID-19.
Bénézit F, Le Turnier P, Declerck C, Paillé C, Revest M, Dubée V, Tattevin P; RAN COVID Study Group. Bénézit F, et al. Lancet Infect Dis. 2020 Sep;20(9):1014-1015. doi: 10.1016/S1473-3099(20)30297-8. Epub 2020 Apr 15. Lancet Infect Dis. 2020. PMID: 32304632 Free PMC article. No abstract available.
Transmitted drug resistance in French HIV-2-infected patients.
Charpentier C, Visseaux B, Bénard A, Peytavin G, Damond F, Roy C, Taieb A, Chêne G, Matheron S, Brun-Vézinet F, Descamps D; ANRS CO5 HIV-2 Cohort. Charpentier C, et al. AIDS. 2013 Jun 19;27(10):1671-4. doi: 10.1097/QAD.0b013e32836207f3. AIDS. 2013. PMID: 23595155
Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?
Frange P, Tubiana R, Sibiude J, Canestri A, Arvieux C, Brunet-Cartier C, Cotte L, Reynes J, Mandelbrot L, Warszawski J, Le Chenadec J; ANRS EPF CO1/CO11 Study Group. Frange P, et al. J Antimicrob Chemother. 2020 May 1;75(5):1324-1331. doi: 10.1093/jac/dkaa017. J Antimicrob Chemother. 2020. PMID: 32157283
Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission.
Chéret A, Bacchus-Souffan C, Avettand-Fenoël V, Mélard A, Nembot G, Blanc C, Samri A, Sáez-Cirión A, Hocqueloux L, Lascoux-Combe C, Allavena C, Goujard C, Valantin MA, Leplatois A, Meyer L, Rouzioux C, Autran B; OPTIPRIM ANRS-147 Study Group. Chéret A, et al. J Antimicrob Chemother. 2015 Jul;70(7):2108-20. doi: 10.1093/jac/dkv084. Epub 2015 Apr 21. J Antimicrob Chemother. 2015. PMID: 25900157 Clinical Trial.
Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
Chéret A, Nembot G, Mélard A, Lascoux C, Slama L, Miailhes P, Yeni P, Abel S, Avettand-Fenoel V, Venet A, Chaix ML, Molina JM, Katlama C, Goujard C, Tamalet C, Raffi F, Lafeuillade A, Reynes J, Ravaux I, Hoën B, Delfraissy JF, Meyer L, Rouzioux C; OPTIPRIM ANRS Study Group. Chéret A, et al. Lancet Infect Dis. 2015 Apr;15(4):387-96. doi: 10.1016/S1473-3099(15)70021-6. Epub 2015 Feb 18. Lancet Infect Dis. 2015. PMID: 25701561 Clinical Trial.
12 results